Skip to main content

Table 1 Patients with hormone positive metastatic breast cancer treated with dovitinib

From: Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib

Pt # Age Index lesion tumor size at baseline (cm) Aromatase inhibitor Total # cycles of dovitinib Dovitinib dose (mg) AE after first cycle Change in tumor size after 8 weeks dovitinib (%) Sites of metastases
001 61 6.5 Exemestane 6 500 Fatigue
GI: nausea, dry mouth
Neuromusc: myalgia, dizziness
− 9.23 Lymph nodes, bone, skin/soft tissue
002 32 15 Anastrozole 1 500 Fatigue
GI: nausea, vomiting, diarrhea, dehydration, poor appetite
Neuromusc: headaches, blurred vision, lightheadedness
Liver: ALP↑
+ 6.0 Lymph nodes, lung, bone
004 65 2.9 Letrozole 2 400 Fatigue, hypertension, bone pain
GI: anorexia, nausea, dyspepsia
+ 24.14 Lung, liver
005 58 5.7 Exemestane 3 400 Fatigue
GI: nausea, vomiting, anorexia, dysgeusia
Neuromusc: muscle weakness
Liver: ALP↑, AST↑
+ 24.56 Lymph nodes, soft tissue, liver
101 64 1 Anastrozole 4 500 Serum amylase↑, creatine↑, magnesium↑
Liver: GGT↑
− 30.0 Lymph nodes, bone
102 57 4.8 Letrozole 2 400 GI: nausea
Liver: GGT↑
0 Lymph nodes, bone
103 52 13.1 Anastrozole 7 400 GI: diarrhea
Neuromusc: back pain
Liver: GGT↑, ALT↑, ALP↑
− 21.37 Lymph nodes, bone, pleura, liver
301 51 1 Letrozole 3 400 Hypokalemia
GI: diarrhea, dyspepsia
Neuromusc: arthralgia
Liver: triglycerides↑, ALT↑, ALP↑, GGT↑
Anemia, Cholesterol↑
+ 10 Lung
  1. pt patient, cm centimeter, mg milligram, AE adverse events, GI gastro intestinal, Neuromusc, neuro muscular, PD progressive disease, ALP alkaline phosphatase, ALT alanine aminotransferase, GGT gamma-glutamyl transpeptidase, AST aspartate aminotransferase, w weeks